免疫疗法与靶向疗法：对抗癌症的一种有前景的联合疗法 - Suppr

[Immunotherapy and targeted therapy, a promising combination to fight cancer].

作者信息

Andrieu Nathan, Bendriss-Vermare Nathalie

机构信息

Master Cancer ISPB, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Université de Lyon, Université Claude Bernard Lyon 1, Inserm U1052, CNRS 5286, centre Léon Bérard, centre de recherche en cancérologie de Lyon, Lyon, 69008, France.

出版信息

Med Sci (Paris). 2018 Oct;34(10):872-875. doi: 10.1051/medsci/2018217. Epub 2018 Nov 19.

DOI:10.1051/medsci/2018217

PMID:30451657

Abstract

摘要

相似文献

[Immunotherapy and targeted therapy, a promising combination to fight cancer].

Med Sci (Paris). 2018 Oct;34(10):872-875. doi: 10.1051/medsci/2018217. Epub 2018 Nov 19.

[Combinations of chemotherapy or radiotherapy with checkpoint inhibitors].

Biol Aujourdhui. 2018;212(3-4):77-79. doi: 10.1051/jbio/2019004. Epub 2019 Apr 11.

[Treatment of the advanced HCC: A second revolution by using immunotherapy].

Biol Aujourdhui. 2018;212(3-4):85-87. doi: 10.1051/jbio/2018027. Epub 2019 Apr 11.

CIMT 2013: advancing targeted therapies--report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany.

Hum Vaccin Immunother. 2013 Sep;9(9):2025-32. doi: 10.4161/hv.25768. Epub 2013 Jul 22.

Checkpoint blockade immunotherapy for cancer comes of age.

J Natl Cancer Inst. 2015 Mar 5;107(3). doi: 10.1093/jnci/djv069. Print 2015 Mar.

HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?

Epigenomics. 2016 Aug;8(8):1015-7. doi: 10.2217/epi-2016-0066. Epub 2016 Jul 13.

Checkpoint inhibitors: outstanding efficacy but at what cost?

Curr Opin Oncol. 2016 Jul;28(4):253. doi: 10.1097/CCO.0000000000000305.

[Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?].

Med Sci (Paris). 2018 Jan;34(1):72-78. doi: 10.1051/medsci/20183401016. Epub 2018 Jan 31.

Advances in Cancer Therapy: Immunotherapies.

Oncol Res Treat. 2016;39(6):324-5. doi: 10.1159/000446635. Epub 2016 May 25.

Multimodality Therapy for NSCLC.

Cancer Treat Res. 2016;170:151-63. doi: 10.1007/978-3-319-40389-2_7.

引用本文的文献

Combined Immunotherapy and Targeted Therapies for Cancer Treatment: Recent Advances and Future Perspectives.

Curr Cancer Drug Targets. 2023;23(4):251-264. doi: 10.2174/1568009623666221020104603.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Immunotherapy and targeted therapy, a promising combination to fight cancer].

作者信息

Andrieu Nathan, Bendriss-Vermare Nathalie

机构信息

Master Cancer ISPB, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Université de Lyon, Université Claude Bernard Lyon 1, Inserm U1052, CNRS 5286, centre Léon Bérard, centre de recherche en cancérologie de Lyon, Lyon, 69008, France.

出版信息

Med Sci (Paris). 2018 Oct;34(10):872-875. doi: 10.1051/medsci/2018217. Epub 2018 Nov 19.

DOI:10.1051/medsci/2018217

PMID:30451657

Abstract

摘要

相似文献

[Immunotherapy and targeted therapy, a promising combination to fight cancer].

Med Sci (Paris). 2018 Oct;34(10):872-875. doi: 10.1051/medsci/2018217. Epub 2018 Nov 19.

[Combinations of chemotherapy or radiotherapy with checkpoint inhibitors].

Biol Aujourdhui. 2018;212(3-4):77-79. doi: 10.1051/jbio/2019004. Epub 2019 Apr 11.

[Treatment of the advanced HCC: A second revolution by using immunotherapy].

Biol Aujourdhui. 2018;212(3-4):85-87. doi: 10.1051/jbio/2018027. Epub 2019 Apr 11.

CIMT 2013: advancing targeted therapies--report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany.

Hum Vaccin Immunother. 2013 Sep;9(9):2025-32. doi: 10.4161/hv.25768. Epub 2013 Jul 22.

Checkpoint blockade immunotherapy for cancer comes of age.

J Natl Cancer Inst. 2015 Mar 5;107(3). doi: 10.1093/jnci/djv069. Print 2015 Mar.

HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?

Epigenomics. 2016 Aug;8(8):1015-7. doi: 10.2217/epi-2016-0066. Epub 2016 Jul 13.

Checkpoint inhibitors: outstanding efficacy but at what cost?

Curr Opin Oncol. 2016 Jul;28(4):253. doi: 10.1097/CCO.0000000000000305.

[Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?].

Med Sci (Paris). 2018 Jan;34(1):72-78. doi: 10.1051/medsci/20183401016. Epub 2018 Jan 31.

Advances in Cancer Therapy: Immunotherapies.

Oncol Res Treat. 2016;39(6):324-5. doi: 10.1159/000446635. Epub 2016 May 25.

Multimodality Therapy for NSCLC.

Cancer Treat Res. 2016;170:151-63. doi: 10.1007/978-3-319-40389-2_7.

引用本文的文献

Combined Immunotherapy and Targeted Therapies for Cancer Treatment: Recent Advances and Future Perspectives.

Curr Cancer Drug Targets. 2023;23(4):251-264. doi: 10.2174/1568009623666221020104603.

[Immunotherapy and targeted therapy, a promising combination to fight cancer].

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

[Immunotherapy and targeted therapy, a promising combination to fight cancer].

作者信息

机构信息

出版信息

相似文献

引用本文的文献